72 related articles for article (PubMed ID: 7248980)
1. Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer.
Russo R; Bartosek I; Piazza E; Santi AM; Libretti A; Garattini S
Cancer Treat Rep; 1981; 65(7-8):555-62. PubMed ID: 7248980
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and immediate effects of high-dose carmustine in man.
Henner WD; Peters WP; Eder JP; Antman K; Schnipper L; Frei E
Cancer Treat Rep; 1986 Jul; 70(7):877-80. PubMed ID: 3719578
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of BCNU in man: a preliminary study of 20 patients.
Levin VA; Hoffman W; Weinkam RJ
Cancer Treat Rep; 1978 Sep; 62(9):1305-12. PubMed ID: 688274
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of fotemustine in rat plasma by electrochemical detection.
Bartosek I; Corada M; Dallarda S; Lucas C; Deloffre P; Guaitani A
Xenobiotica; 1991 Feb; 21(2):235-42. PubMed ID: 2058178
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of nitrosoureas: comparison of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) after oral and intravenous administration to rats.
Russo RG; Cattaneo MT; Bartosek I
Tumori; 1984 Dec; 70(6):499-502. PubMed ID: 6531792
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET.
Tyler JL; Yamamoto YL; Diksic M; Théron J; Villemure JG; Worthington C; Evans AC; Feindel W
J Nucl Med; 1986 Jun; 27(6):775-80. PubMed ID: 3486962
[TBL] [Abstract][Full Text] [Related]
9. Differential plus polarographic determination of submicrogram quantities of carmustine and related compounds in biological samples.
Bartosek I; Daniel S; Sýkora S
J Pharm Sci; 1978 Aug; 67(8):1160-3. PubMed ID: 671258
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans.
Rowinsky EK; Noe DA; Ettinger DS; Christian MC; Lubejko BG; Fishman EK; Sartorius SE; Boyd MR; Donehower RC
Cancer Res; 1993 Apr; 53(8):1794-801. PubMed ID: 8467498
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of nitrosoureas: levels of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in organs of normal and Walker 256/B carcinoma bearing rats after i.v. bolus.
Bartosek I; Russo RG; Cattaneo MT
Tumori; 1984 Dec; 70(6):491-8. PubMed ID: 6531791
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of cyclophosphamide in patients under polychemotherapeutic regimens.
Ottolenghi L; Morasca L; Marsoni S; Piazza E; Soresi E; Libretti A; Garattini S
Biomedicine; 1980 Oct; 32(3):123-7. PubMed ID: 7448321
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of etomidate in man (author's transl)].
Schüttler J; Wilms M; Lauven PM; Stoeckel H; Koenig A
Anaesthesist; 1980 Dec; 29(12):658-61. PubMed ID: 7212248
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of vincristine sulfate in adult cancer patients.
Sethi VS; Jackson DV; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Spurr CL
Cancer Res; 1981 Sep; 41(9 Pt 1):3551-5. PubMed ID: 7260915
[TBL] [Abstract][Full Text] [Related]
16. Polarographic assay of submicrogram quantities of cis-dichlorodiamineplatinum (II) in biological samples.
Bartosek I; Cattaneo MT; Grasselli G; Guaitani A; Urso R; Zucca E; Libretti A; Garattini S
Tumori; 1983 Oct; 69(5):395-402. PubMed ID: 6685932
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
18. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
de Jong RS; Mulder NH; Uges DR; Sleijfer DT; Höppener FJ; Groen HJ; Willemse PH; van der Graaf WT; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):882-7. PubMed ID: 10070885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
